DD283645A5 - Verfahren zur herstellung von neuen eglin-mutanten - Google Patents

Verfahren zur herstellung von neuen eglin-mutanten Download PDF

Info

Publication number
DD283645A5
DD283645A5 DD89326310A DD32631089A DD283645A5 DD 283645 A5 DD283645 A5 DD 283645A5 DD 89326310 A DD89326310 A DD 89326310A DD 32631089 A DD32631089 A DD 32631089A DD 283645 A5 DD283645 A5 DD 283645A5
Authority
DD
German Democratic Republic
Prior art keywords
eglin
dna
asp
thr
acetyl
Prior art date
Application number
DD89326310A
Other languages
German (de)
English (en)
Inventor
Markus Gruetter
Dirk Heinz
Manfred Liersch
Original Assignee
����`��@���k��
���@���`������@��k��
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ����`��@���k��, ���@���`������@��k�� filed Critical ����`��@���k��
Publication of DD283645A5 publication Critical patent/DD283645A5/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/815—Protease inhibitors from leeches, e.g. hirudin, eglin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8261—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield
    • C12N15/8271—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance
    • C12N15/8279—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance for biotic stress resistance, pathogen resistance, disease resistance
    • C12N15/8286—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance for biotic stress resistance, pathogen resistance, disease resistance for insect resistance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
    • Y02A40/10—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in agriculture
    • Y02A40/146—Genetically Modified [GMO] plants, e.g. transgenic plants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/855—Proteins from animals other than mammals or birds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Insects & Arthropods (AREA)
  • Pest Control & Pesticides (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
DD89326310A 1988-03-07 1989-03-06 Verfahren zur herstellung von neuen eglin-mutanten DD283645A5 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH84088 1988-03-07

Publications (1)

Publication Number Publication Date
DD283645A5 true DD283645A5 (de) 1990-10-17

Family

ID=4196431

Family Applications (1)

Application Number Title Priority Date Filing Date
DD89326310A DD283645A5 (de) 1988-03-07 1989-03-06 Verfahren zur herstellung von neuen eglin-mutanten

Country Status (20)

Country Link
US (1) US5079229A (ko)
EP (1) EP0332576B1 (ko)
JP (1) JP2716191B2 (ko)
KR (1) KR0134377B1 (ko)
AT (1) ATE103930T1 (ko)
AU (1) AU623881B2 (ko)
CA (1) CA1339105C (ko)
DD (1) DD283645A5 (ko)
DE (1) DE58907373D1 (ko)
DK (1) DK107389A (ko)
ES (1) ES2063161T3 (ko)
FI (1) FI96116C (ko)
HU (1) HU209401B (ko)
IE (1) IE62993B1 (ko)
IL (1) IL89496A0 (ko)
NO (1) NO178870C (ko)
NZ (1) NZ228208A (ko)
PT (1) PT89916B (ko)
TW (1) TW211522B (ko)
ZA (1) ZA891679B (ko)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6342373B1 (en) * 1983-11-21 2002-01-29 Ucp Gen-Pharma Ag Process for preparing recombinant eglin, protease inhibitor
US5674833A (en) * 1990-09-18 1997-10-07 Novo Nordisk A/S Detergent compositions containing protease and novel inhibitors for use therein
US5604201A (en) * 1993-01-08 1997-02-18 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non-Profit Organization Methods and reagents for inhibiting furin endoprotease
TW492975B (en) * 1993-07-26 2002-07-01 Novartis Ag Tryptase inhibitor
WO1998013387A1 (en) 1996-09-24 1998-04-02 The Procter & Gamble Company Stabilized proteinaceous protease inhibitors and variants thereof
US7001884B2 (en) * 2001-06-18 2006-02-21 Regents Of The University Of Michigan Eglin c based drugs for treatment of disease

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2125047B (en) * 1982-08-09 1986-02-19 Ciba Geigy Ag Yeast hybrid vectors and their use for the production of polypeptides
DE3324534A1 (de) * 1983-07-07 1985-01-17 Ciba-Geigy Ag, Basel Modifizierte protease-inhibitoren, verfahren zu ihrer herstellung und daraus bereitete pharmazeutische mittel
CA1297437C (en) * 1983-11-21 1992-03-17 Hans Rink Process for the preparation of protease inhibitors
US4711848A (en) * 1984-03-14 1987-12-08 Zymogenetics, Inc. Site specific mutagenesis in alpha-1-antitrypsin
EP0164719B1 (en) * 1984-06-14 1992-05-06 Chiron Corporation Active site modified protease alpha-1-antitrypsin inhibitors and their production
HU204563B (en) * 1984-12-06 1992-01-28 Synergen Biolog Inc Process for producing recombinant serine-protease inhibitors and dns sequencyes for them
GB2188322A (en) * 1986-03-26 1987-09-30 Bayer Ag Aprotinin and analogues thereof produced by a recombinant host
GB2199582A (en) * 1987-01-07 1988-07-13 Bayer Ag Analogues of pancreatic secretory trypsin inhibitor

Also Published As

Publication number Publication date
HUT50503A (en) 1990-02-28
IL89496A0 (en) 1989-09-10
PT89916B (pt) 1994-05-31
KR890014735A (ko) 1989-10-25
NO890932D0 (no) 1989-03-06
FI891020A0 (fi) 1989-03-03
US5079229A (en) 1992-01-07
NO890932L (no) 1989-09-08
NZ228208A (en) 1990-08-28
FI96116B (fi) 1996-01-31
FI891020A (fi) 1989-09-08
NO178870C (no) 1996-06-19
KR0134377B1 (ko) 1998-04-20
FI96116C (fi) 1996-05-10
ES2063161T3 (es) 1995-01-01
IE62993B1 (en) 1995-03-08
EP0332576A3 (en) 1990-09-12
ATE103930T1 (de) 1994-04-15
CA1339105C (en) 1997-07-29
ZA891679B (en) 1989-10-25
EP0332576B1 (de) 1994-04-06
AU3095989A (en) 1989-09-07
PT89916A (pt) 1989-11-10
DK107389A (da) 1989-09-08
DE58907373D1 (de) 1994-05-11
AU623881B2 (en) 1992-05-28
HU209401B (en) 1994-05-30
JPH029392A (ja) 1990-01-12
TW211522B (ko) 1993-08-21
IE890719L (en) 1989-09-07
DK107389D0 (da) 1989-03-06
NO178870B (no) 1996-03-11
JP2716191B2 (ja) 1998-02-18
EP0332576A2 (de) 1989-09-13

Similar Documents

Publication Publication Date Title
EP0307592B1 (de) Varianten des pankreatischen Rinder-Trypsininhibitors, deren Herstellung und Verwendung
DE3650306T2 (de) Expressions- und Ausscheidungsvektoren für Hirudin mittels transformierter Hefe.
EP0168342B1 (de) Verfahren zur Herstellung von Thrombin-Inhibitoren
EP0209061B1 (de) Neue Polypeptide mit blutgerinnungshemmender Wirkung, Verfahren zu deren Herstellung bzw. Gewinnung, deren Verwendung und diese enthaltende Mittel
DE68923123T2 (de) Herstellung von Proteinen.
DE3382658T2 (de) Glycolytische promotoren fuer regulierte proteinexpression: protease-inhibitor.
DE58907266T2 (de) Polypeptide mit einer die Koagulierung hemmenden Wirkung.
DE3686399T2 (de) Herstellung von thrombin-inhibitoren.
EP0393431A1 (de) Gentechnologisch hergestellte Homologe des Alzheimer-Protease-Inhibitors, Wirtstämme sowie Expressionsvektoren für ihre Herstellung für ihre Verwendung als Arzneimittel
EP0232523B1 (de) DNA-Sequenzen, die für Proteine mit der biologischen Aktivität der HUSI-TypI-Inhibitoren codieren, gentechnologische Verfahren zur Herstellung dieser Proteine und diese Proteine enthaltende Arzneimittel
EP0332576B1 (de) Modifizierte Proteine
DE3930522A1 (de) Rekombinante aprotinin-varianten - gentechnisches verfahren zur mikrobiellen herstellung von homogen prozessierten aprotinin-varianten sowie die therapeutische anwendung derselben
DE3724570A1 (de) Human-aprotinin, dessen lys-rest in position 15 gegen einen anderen protogenen aminosaeurerest ausgetauscht ist
DE3724581A1 (de) Dna-sequenzen, die fuer proteine mit den biologischen eigenschaften des cystatin c codieren, herstellung dieser dna-sequenzen, expression des cystatin c sowie dieses enthaltende pharmazeutische zubereitungen
DD284045A5 (de) Verfahren zur herstellung von desulfarohirudinmutanten
EP0244627A2 (de) Expressionsvektoren zur Gewinnung von Polypeptiden
US5268296A (en) DNA vector and recombinant host cell for production of hirullin P6 and P18
DD284044A5 (de) Verfahren zur herstellung von desulfatohirudinmutanten
US5180667A (en) Genes encoding eglin C mutants
WO2002004486A2 (de) Bifunktionale fusionsproteine aus hirudin und tap
DE69432975T2 (de) Tryptase hemmer
EP0373335A2 (de) Neue Serinprotease-Inhibitor-Proteine, diese enthaltende Arzneimittel, DNA-Sequenzen die für diese Proteine codieren und Verfahren zur Herstellung dieser Proteine, Arzneimittel und DNA-Sequenzen
DD233853A5 (de) Verfahren zur herstellung von eglin-verbindungen

Legal Events

Date Code Title Description
ENJ Ceased due to non-payment of renewal fee